Home > Insider Trading > Filing (0001596771-19-000017)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1506492	Chf Solutions Inc.	CHFS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1213867	L John Erb	12988 Valley View Road Eden Prairie MN 55344	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-03-12	9,523	$5.25	11,615	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series 1 Warrant to Purchase Common Stock (right to buy)	Acquisiton	2019-03-12	9,523	$0.00	9,523	$5.25
Common Stock	Series 2 Warrant to Purchase Common Stock (right to buy)	Acquisiton	2019-03-12	9,523	$0.00	9,523	$5.25

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,523	2019-03-12	2024-03-12	No	4	P	Direct
9,523	2019-03-12		No	4	P	Direct

Footnotes

The reporting person purchased Class A Units, which consisted of one share of common stock, a Series 1 warrant to purchase one share of common stock, and a Series 2 warrant to purchase one share of common stock, in an underwritten public offering by the issuer at a price of $5.25 per unit. The offering closed on March 12, 2019.
On January 2, 2019, the issuer effected a 1-for-14 reverse stock split of the issued and outstanding shares of its common stock. Upon effectiveness of the reverse stock split, every 14 shares of common stock was automatically converted into one share of common stock.
The Series 2 warrant expires on the earlier of the eighteen-month anniversary of the date of issuance and the 30th trading day following public announcement by the issuer of receipt from the U.S. Food and Drug Administration of clearance or approval of a modification to the product label for the Aquadex FlexFlow system to include pediatric patients.